🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for MSS Metastatic Colorectal Cancer

Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer. NCT06613113NA1 site📍 Ningbo Ningbo Medical Center Lihuili Hospital · Tests: Fruquintinib Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status. NCT07595276Phase 31 site📍 Guangzhou Taizhou Mabtech Pharmaceutical Co.,Ltd · Tests: Enlituo®, Erbitux® New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer NCT07559760Phase 21 site📍 Changchun The First Hospital of Jilin University · Tests: Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy NCT06549907n/a1 site📍 Beijing Peking University Cancer Hospital & Institute · Tests: Multi-omics testing, MRI Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer NCT06282445Phase 21 site📍 Jinhua The Fourth Affiliated Hospital of Zhejiang University Schoo… · Tests: Adebrelimab, Oxaliplatin, Capecitabine, Bevacizumab FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264Phase 1, Phase 233 sites📍 Phoenix📍 Scottsdale📍 Tucson Parabilis Medicines, Inc. · Tests: FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer NCT07506109Phase 24 sites📍 Beijing📍 Wuhan📍 Chengdu Tianjin Medical University Cancer Institute and Hospital · Tests: Ipilimumab N01, Sintilimab, Cetuximab, Dabrafenib Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC NCT07281716Phase 1, Phase 21 site📍 New York Dan Feng · Tests: Nadunolimab, Toripalimab Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) NCT06589440Phase 26 sites📍 Morristown📍 Austin📍 Dallas Stingray Therapeutics · Tests: SR-8541A Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer NCT06764680Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Trifluorouracil tepidopyrimidine, Bevacizumab, Sindilizumab, IMRT Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) NCT06634875Phase 23 sites📍 Los Angeles📍 Newport Beach📍 Atlanta Buzzard Pharmaceuticals · Tests: isunakinra - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases NCT06856837Phase 223 sites📍 Linz📍 Salzburg📍 Wiener Neustadt Institut für Klinische Krebsforschung IKF GmbH at Krankenha… · Tests: Fruquintinib, Tislelizumab, Trifluridine/tipiracil, Bevacizumab Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer NCT06176885Phase 21 site📍 Jinhua yue junhan · Tests: Camrelizumab Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer NCT06522919Phase 22 sites📍 Meldola📍 Tricase Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IR… · Tests: Autologous Dendritic Cell (DC) Vaccine Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC) NCT06958419Phase 2, Phase 31 site📍 Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University · Tests: Node-Sparing Radiotherapy plus first-line therapy, First-line treatment A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study NCT05954429Phase 22 sites📍 Shanghai📍 Shanghai Fudan University · Tests: serplulimab, Fruquintinib Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC NCT06456515NA1 site📍 Changzhou The First People's Hospital of Changzhou · Tests: Regorafenib and Sintilimab in combination with electroacupuncture A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer NCT07321106Phase 110 sites📍 Phoenix📍 Duarte📍 Los Angeles Cartography Biosciences · Tests: CBI-1214 A Study of ASP1002 in Adults for Treatment of Solid Tumors NCT05719558Phase 115 sites📍 New Haven📍 Plainville📍 Gainesville Astellas Pharma Global Development, Inc. · Tests: ASP1002, Bevacizumab, Oxaliplatin, Leucovorin, Fluorouracil A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer NCT07079631Phase 1, Phase 214 sites📍 New Haven📍 Grand Rapids📍 Cleveland BioNTech SE · Tests: BNT314, Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer NCT06685276Phase 21 site📍 Beijing Dai, Guanghai · Tests: Fruquintinib, Sintilimab, Chidamide Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer NCT06566755Phase 31 site📍 Shenyang Caigang Liu · Tests: Cadonilimab (AK104) combined with chemotherapy and bevacizumab BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases NCT07550088Phase 21 site📍 La Jolla Darren Sigal, MD · Tests: Balstilimab (BAL), Botensilimab (BOT), agenT-797 KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer NCT05985109Phase 21 site📍 Beijing Peking University Cancer Hospital & Institute · Tests: KN046, regorafenib A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors NCT07540572Phase 111 sites📍 Plantation📍 East Brunswick📍 Lake Success IDEAYA Biosciences · Tests: IDE574, Fulvestrant injection Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer NCT06218810Phase 21 site📍 Shanghai Fudan University · Tests: Cadonilimab + bevacizumab + FOLFOX FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. NCT06733038Phase 324 sites📍 Brescia📍 Catania📍 Meldola Gruppo Oncologico del Nord-Ovest · Tests: Atezolizumab, Bevacizumab, Irinotecan (CPT-11), Oxaliplatin, Leucovorin A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer NCT06978400Phase 21 site📍 Moscow Blokhin's Russian Cancer Research Center · Tests: mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC NCT06321081Phase 21 site📍 Beijing Beijing Hospital · Tests: irinotecan, cetuximab, envafolimab Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC NCT06551207NA1 site📍 Wuhan Liu Huang · Tests: Fruquintinib, Cadonilimab, SBRT
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy